On December 18, 2023, Amring Pharmaceuticals Inc., a subsidiary of Nordic Group B.V. (Nordic Pharma), announced the completion of its acquisition of Visant Medical, Inc., a leader in medical technology innovation in Dry Eye Disease (DED). Wilson Sonsini Goodrich & Rosati advised Visant Medical on the transaction.
This acquisition unites Nordic Pharma's pharmaceutical expertise with Visant's FDA-cleared hyaluronic acid derivative LACRIFILL® canalicular occlusive device, which is intended to temporarily block tear drainage by the occlusion of the canalicular system. Nordic Pharma will launch and commercialize LACRIFILL in the U.S. and has been chosen because of its focus on ophthalmology.
The Wilson Sonsini team that advised Visant Medical included:
Corporate
Elton Satusky
Jesse Schumaker
Roy Argand
Laura Jetter
Esther Lim
Katherine Fuller
Patents and Innovations
Darby Chan
Technology Transactions
Alex Key
Employee Benefits and Compensation
Michael Klippert
Emma Wilcox
Regulatory
Eva Yin
Anne Seymour
National Security
Joshua Gruenspecht
Litigation
Alex Katsnelson
For more information, please see Nordic Pharma’s press release.